We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
- Authors
Aronson, Stephen; Van Baelen, Bart; Kavanagh, Shane; Schwalen, Susanne
- Abstract
Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer's type. Although several drugs are indicated for mild to moderate Alzheimer's disease (AD), no published study has separately analysed mild and moderate AD subgroups to assess the effect of dosage.
- Publication
Drugs & aging, 2009, Vol 26, Issue 3, p231
- ISSN
1170-229X
- Publication type
Journal Article
- DOI
10.2165/00002512-200926030-00004